23 October 2017Americas

Generic Restasis plans revealed days after patent invalidation

A San Diego-based company has announced plans to sell a generic version of Allergan’s dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), just days after four patents covering the drug were invalidated.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.

More on this story

Americas
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.

More on this story

Americas
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.